These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 20022493)

  • 21. The identification and optimization of orally efficacious, small molecule VLA-4 antagonists.
    Huryn DM; Konradi AW; Ashwell S; Freedman SB; Lombardo LJ; Pleiss MA; Thorsett ED; Yednock T; Kennedy JD
    Curr Top Med Chem; 2004; 4(14):1473-84. PubMed ID: 15544538
    [TBL] [Abstract][Full Text] [Related]  

  • 22. VLA-4 antagonists: potent inhibitors of lymphocyte migration.
    Yang GX; Hagmann WK
    Med Res Rev; 2003 May; 23(3):369-92. PubMed ID: 12647315
    [TBL] [Abstract][Full Text] [Related]  

  • 23. N-Aroyl-L-phenylalanine derivatives as VCAM/VLA-4 antagonists.
    Sidduri A; Tilley JW; Lou JP; Chen L; Kaplan G; Mennona F; Campbell R; Guthrie R; Huang TN; Rowan K; Schwinge V; Renzetti LM
    Bioorg Med Chem Lett; 2002 Sep; 12(17):2479-82. PubMed ID: 12161162
    [TBL] [Abstract][Full Text] [Related]  

  • 24. N-isonicotinoyl-(L)-4-aminophenylalanine derivatives as tight binding VLA-4 antagonists.
    Doherty GA; Yang GX; Borges E; Tong S; McCauley ED; Treonz KM; Van Riper G; Pacholok S; Si Q; Koo GC; Shah K; Mumford RA; Hagmann WK
    Bioorg Med Chem Lett; 2003 Jun; 13(11):1891-5. PubMed ID: 12749892
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pyridone derivatives as potent and selective VLA-4 integrin antagonists.
    Witherington J; Bordas V; Gaiba A; Green PM; Naylor A; Parr N; Smith DG; Takle AK; Ward RW
    Bioorg Med Chem Lett; 2006 Apr; 16(8):2256-9. PubMed ID: 16455247
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aza-bicyclic amino acid carboxamides as alpha4beta1/alpha4beta7 integrin receptor antagonists.
    Dyatkin AB; Gong Y; Miskowski TA; Kimball ES; Prouty SM; Fisher MC; Santulli RJ; Schneider CR; Wallace NH; Hornby PJ; Diamond C; Kinney WA; Maryanoff BE; Damiano BP; He W
    Bioorg Med Chem; 2005 Dec; 13(24):6693-702. PubMed ID: 16112583
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of N-{N-[(3-cyanophenyl)sulfonyl]-4(R)-cyclobutylamino-(L)-prolyl}-4-[(3',5'-dichloroisonicotinoyl) amino]-(L)-phenylalanine (MK-0668), an extremely potent and orally active antagonist of very late antigen-4.
    Lin LS; Lanza T; Jewell JP; Liu P; Jones C; Kieczykowski GR; Treonze K; Si Q; Manior S; Koo G; Tong X; Wang J; Schuelke A; Pivnichny J; Wang R; Raab C; Vincent S; Davies P; Maccoss M; Mumford RA; Hagmann WK
    J Med Chem; 2009 Jun; 52(11):3449-52. PubMed ID: 19441819
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of a potent, orally bioavailable pyrimidine VLA-4 antagonist effective in a sheep asthma model.
    Semko CM; Chen L; Dressen DB; Dreyer ML; Dunn W; Farouz FS; Freedman SB; Holsztynska EJ; Jefferies M; Konradi AW; Liao A; Lugar J; Mutter L; Pleiss MA; Quinn KP; Thompson T; Thorsett ED; Vandevert C; Xu YZ; Yednock TA
    Bioorg Med Chem Lett; 2011 Mar; 21(6):1741-3. PubMed ID: 21316228
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and biological evaluation of novel pyridazinone-based alpha4 integrin receptor antagonists.
    Gong Y; Barbay JK; Dyatkin AB; Miskowski TA; Kimball ES; Prouty SM; Fisher MC; Santulli RJ; Schneider CR; Wallace NH; Ballentine SA; Hageman WE; Masucci JA; Maryanoff BE; Damiano BP; Andrade-Gordon P; Hlasta DJ; Hornby PJ; He W
    J Med Chem; 2006 Jun; 49(11):3402-11. PubMed ID: 16722660
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dipeptide proline diphenyl phosphonates are potent, irreversible inhibitors of seprase (FAPalpha).
    Gilmore BF; Lynas JF; Scott CJ; McGoohan C; Martin L; Walker B
    Biochem Biophys Res Commun; 2006 Jul; 346(2):436-46. PubMed ID: 16769036
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficient synthesis of 3-aminocyclobut-2-en-1-ones: squaramide surrogates as potent VLA-4 antagonists.
    Brand S; de Candole BC; Brown JA
    Org Lett; 2003 Jun; 5(13):2343-6. PubMed ID: 12816444
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of alpha(4)beta(1) (CD49d/CD29) on equine leukocytes: potential utility of a potent alpha(4)beta(1) (CD49d/CD29) receptor antagonist in the treatment of equine heaves (recurrent airway obstruction).
    Treonze KM; Alves K; Fischer P; Hagmann WK; Hora D; Kulick A; Vakerich K; Smith ND; Lingham RB; Maniar S; Reger TS; Zunic J; Munoz B; Prasit P; Nicholson D; Si Q; Judd K; Nicolich S; Kellerhouse P; Thompson D; Mumford RA
    Vet Immunol Immunopathol; 2009 Jul; 130(1-2):79-87. PubMed ID: 19250687
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design, synthesis, and evaluation of proline and pyrrolidine based melanocortin receptor agonists. A conformationally restricted dipeptide mimic approach.
    Tian X; Field TB; Switzer AG; Mazur AW; Ebetino FH; Wos JA; Berberich SM; Jayasinghe LR; Obringer CM; Dowty ME; Pinney BB; Farmer JA; Crossdoersen D; Sheldon RJ
    J Med Chem; 2006 Jul; 49(15):4745-61. PubMed ID: 16854081
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ligand binding of leukocyte integrin very late antigen-4 involves exposure of sulfhydryl groups and is subject to redox modulation.
    Liu SY; Tsai MY; Chuang KP; Huang YF; Shieh CC
    Eur J Immunol; 2008 Feb; 38(2):410-23. PubMed ID: 18196516
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human PEPT1 pharmacophore distinguishes between dipeptide transport and binding.
    Vig BS; Stouch TR; Timoszyk JK; Quan Y; Wall DA; Smith RL; Faria TN
    J Med Chem; 2006 Jun; 49(12):3636-44. PubMed ID: 16759105
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 2,6-Quinolinyl derivatives as potent VLA-4 antagonists.
    Lassoie MA; Broeders F; Collart P; Defrère L; de Laveleye-Defais F; Demaude T; Gassama A; Guillaumet G; Hayez JC; Kiss L; Knerr L; Nicolas JM; Norsikian S; Quéré L; Routier S; Verbois V; Provins L
    Bioorg Med Chem Lett; 2007 Jan; 17(1):142-6. PubMed ID: 17035017
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthetic study of VLA-4/VCAM-1 inhibitors: synthesis and structure-activity relationship of piperazinylphenylalanine derivatives.
    Saku O; Ohta K; Arai E; Nomoto Y; Miura H; Nakamura H; Fuse E; Nakasato Y
    Bioorg Med Chem Lett; 2008 Feb; 18(3):1053-7. PubMed ID: 18160288
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chiral recognition of dipeptides in a biomembrane model.
    Bombelli C; Borocci S; Lupi F; Mancini G; Mannina L; Segre AL; Viel S
    J Am Chem Soc; 2004 Oct; 126(41):13354-62. PubMed ID: 15479092
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 2-Nitrophenylcarbamoyl-(S)-prolyl-(S)-3-(2-naphthyl)alanyl-N-benzyl-N - methylamide (SDZ NKT 343), a potent human NK1 tachykinin receptor antagonist with good oral analgesic activity in chronic pain models.
    Walpole C; Ko SY; Brown M; Beattie D; Campbell E; Dickenson F; Ewan S; Hughes GA; Lemaire M; Lerpiniere J; Patel S; Urban L
    J Med Chem; 1998 Aug; 41(17):3159-73. PubMed ID: 9703462
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis and evaluation of 4,5-dihydro-5-methylisoxazolin-5-carboxamide derivatives as VLA-4 antagonists.
    Soni A; Rehman A; Naik K; Dastidar S; Alam MS; Ray A; Chaira T; Shah V; Palle VP; Cliffe IA; Sattigeri VJ
    Bioorg Med Chem Lett; 2013 Mar; 23(5):1482-5. PubMed ID: 23312947
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.